Skip to main content
NOVOPROTEIN SCIENTIFIC INC. logo

NOVOPROTEIN SCIENTIFIC INC. — Investor Relations & Filings

Ticker · 688137 ISIN · CNE100005NZ4 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 305 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688137

About NOVOPROTEIN SCIENTIFIC INC.

https://www.novoprotein.com.cn/

Novoprotein Scientific Inc. specializes in the development and manufacture of high-quality recombinant proteins and enzymes for life sciences and biopharmaceutical applications. The company provides a comprehensive portfolio of products, including cytokines, growth factors, viral antigens, and diagnostic enzymes, which are utilized in research, drug discovery, and the development of cell and gene therapies. Novoprotein offers specialized services such as custom protein expression and purification across various platforms, including mammalian, insect, and microbial systems. By leveraging advanced protein engineering and large-scale production technologies, the company supports global research institutions and commercial partners in advancing medical diagnostics and therapeutic innovation. Its focus remains on delivering bioactive reagents that meet rigorous quality standards for consistency and performance.

Recent filings

Filing Released Lang Actions
国联民生证券承销保荐有限公司关于苏州近岸蛋白质科技股份有限公司首次公开发行股票并在科创板上市之持续督导保荐总结报告书
Regulatory Filings Classification · 87% confidence The document is a continuous supervision summary report prepared by the IPO sponsor (“保荐机构”) covering their ongoing compliance oversight of the company post-IPO. It is not an annual or interim financial report, nor a proxy statement, earnings release, or management commentary. Instead, it serves as a statutory compliance filing summarizing due diligence, supervisory actions, and disclosures under Shanghai Stock Exchange and China Securities Regulatory Commission rules. This falls under general regulatory announcements and compliance documents, making it a Regulatory Filing (RNS).
2026-05-15 Chinese
2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is a comprehensive set of materials for the 2025 Annual General Meeting of Suzhou Novoprotein Protein Technology Co., Ltd., including meeting instructions, agenda, and multiple proposals to be considered at the AGM. This clearly aligns with “Presentations and materials shared during the Annual General Meeting (AGM).” There is no financial data or report itself, nor is it a simple announcement or proxy statement. Therefore, it should be classified as AGM Information (AGM-R).
2026-05-14 Chinese
国联民生证券承销保荐有限公司关于苏州近岸蛋白质科技股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 86% confidence The document is a “持续督导跟踪报告” (continuous supervision tracking report) issued by the IPO sponsor for a company listed on the Sci-Tech Innovation Board, detailing sponsor work, compliance checks, risk assessment, financial metrics, and fund usage. It is neither an annual or interim financial report nor an announcement of board changes, dividends, or M&A. Rather, it is a regulatory compliance filing under listing rules and falls into the miscellaneous regulatory filings category (RNS).
2026-05-11 Chinese
关于注销部分回购股份减少注册资本暨通知债权人的公告
Regulatory Filings
2026-05-08 Chinese
2026年第一次临时股东会决议公告
Regulatory Filings
2026-05-08 Chinese
2025年度独立董事述职报告（金坚）
Management Reports Classification · 95% confidence The document is titled as the "2025年度独立董事述职报告" which translates to "2025 Annual Independent Director's Work Report". It is a detailed report by an independent director about their duties, attendance, and activities during the year 2025. The content includes descriptions of the director's background, attendance at board and committee meetings, communication with auditors, oversight of financial reporting, and governance matters. It does not contain financial statements or quarterly/annual financial results but focuses on the independent director's role and governance oversight. This type of document is a management or governance-related report detailing the independent director's work and observations, which fits best under the category of Management Reports (MDA). The document length is about 4613 characters, which is sufficient for a substantive report rather than a brief announcement. It is not an announcement of voting results, not a proxy statement, nor a regulatory filing or certification. Therefore, the most appropriate classification is Management Reports (MDA).
2026-04-28 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.